NATIONAL CANCER INSTITUTENIH · NATIONAL CANCER INSTITUTENIH

Th17 T cell-inducing vaccines for the prevention of ovarian cancer recurrence

Knutson, Keith L. (Contact)·Mayo Clinic Rochester, MN·2009–2026·ACTIVE

Donate

INSTITUTION

Mayo Clinic Rochester, MN

PRINCIPAL INVESTIGATOR

Knutson, Keith L. (Contact)

FUNDING

$211K

YEAR

2009

MOONBASE SCORE

Still being scored

LOADING MOONBASE SCORE

Abstract

The overall goal of this project is to perform preclinical and phase II clinical testing of a Th17-induced pulsed dendritic cell vaccine to assess its efficacy in preventing relapse of high grade ovarian cancer in first remission after debulking surgery and platinum-based adjuvant or neoadjuvant chemotherapy.

NATIONAL CANCER INSTITUTEP50ZCA1-RPRB-8phaseclinicaldebulkingovariandendriticremissionassessinducedoverallpreclinicalpreventingafteradjuvantrelapseefficacypulsedsurgery

Are you the primary organization running this research?

The two tools below are built for the principal investigator & host institution behind this project.